vs
Andersons, Inc.（ANDE）与Apellis Pharmaceuticals, Inc.（APLS）财务数据对比。点击上方公司名可切换其他公司
Andersons, Inc.的季度营收约是Apellis Pharmaceuticals, Inc.的1.6倍（$329.5M vs $199.9M），Andersons, Inc.净利率更高（20.5% vs -29.5%，领先50.0%），Andersons, Inc.同比增速更快（-2.4% vs -5.9%），Apellis Pharmaceuticals, Inc.自由现金流更多（$-14.3M vs $-77.1M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -1.8%）
安德森公司（The Andersons, Inc.）是1947年成立的美国农业企业，总部位于俄亥俄州莫米。公司起源于1940年代服务粮食行业的安德森货运站，是深耕农业领域的多元化企业，业务覆盖大宗商品贸易、可再生能源以及植物营养板块。
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
ANDE vs APLS — 直观对比
营收规模更大
ANDE
是对方的1.6倍
$199.9M
营收增速更快
ANDE
高出3.6%
-5.9%
净利率更高
ANDE
高出50.0%
-29.5%
自由现金流更多
APLS
多$62.8M
$-77.1M
两年增速更快
APLS
近两年复合增速
-1.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $329.5M | $199.9M |
| 净利润 | $67.4M | $-59.0M |
| 毛利率 | 70.3% | — |
| 营业利润率 | 26.6% | -25.6% |
| 净利率 | 20.5% | -29.5% |
| 营收同比 | -2.4% | -5.9% |
| 净利润同比 | 49.6% | -62.2% |
| 每股收益（稀释后） | — | $-0.40 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ANDEAPLS
| Q4 25 | $329.5M | $199.9M | ||
| Q3 25 | $295.8M | $458.6M | ||
| Q2 25 | $535.0M | $178.5M | ||
| Q1 25 | $370.8M | $166.8M | ||
| Q4 24 | $337.5M | $212.5M | ||
| Q3 24 | $231.9M | $196.8M | ||
| Q2 24 | $492.5M | $199.7M | ||
| Q1 24 | $341.4M | $172.3M |
净利润ANDEAPLS
| Q4 25 | $67.4M | $-59.0M | ||
| Q3 25 | $20.1M | $215.7M | ||
| Q2 25 | $7.9M | $-42.2M | ||
| Q1 25 | $284.0K | $-92.2M | ||
| Q4 24 | $45.1M | $-36.4M | ||
| Q3 24 | $27.4M | $-57.4M | ||
| Q2 24 | $36.0M | $-37.7M | ||
| Q1 24 | $5.6M | $-66.4M |
毛利率ANDEAPLS
| Q4 25 | 70.3% | — | ||
| Q3 25 | 57.8% | — | ||
| Q2 25 | 29.6% | — | ||
| Q1 25 | 41.2% | — | ||
| Q4 24 | 63.1% | — | ||
| Q3 24 | 76.4% | — | ||
| Q2 24 | 35.6% | — | ||
| Q1 24 | 37.6% | — |
营业利润率ANDEAPLS
| Q4 25 | 26.6% | -25.6% | ||
| Q3 25 | 8.7% | 48.7% | ||
| Q2 25 | 4.6% | -18.6% | ||
| Q1 25 | 0.9% | -50.0% | ||
| Q4 24 | 19.9% | -12.3% | ||
| Q3 24 | 26.8% | -24.0% | ||
| Q2 24 | 11.6% | -14.7% | ||
| Q1 24 | 4.1% | -36.0% |
净利率ANDEAPLS
| Q4 25 | 20.5% | -29.5% | ||
| Q3 25 | 6.8% | 47.0% | ||
| Q2 25 | 1.5% | -23.6% | ||
| Q1 25 | 0.1% | -55.3% | ||
| Q4 24 | 13.4% | -17.1% | ||
| Q3 24 | 11.8% | -29.2% | ||
| Q2 24 | 7.3% | -18.9% | ||
| Q1 24 | 1.6% | -38.5% |
每股收益（稀释后）ANDEAPLS
| Q4 25 | — | $-0.40 | ||
| Q3 25 | $0.59 | $1.67 | ||
| Q2 25 | $0.23 | $-0.33 | ||
| Q1 25 | $0.01 | $-0.74 | ||
| Q4 24 | $1.31 | $-0.30 | ||
| Q3 24 | $0.80 | $-0.46 | ||
| Q2 24 | $1.05 | $-0.30 | ||
| Q1 24 | $0.16 | $-0.54 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $98.3M | $466.2M |
| 总债务越低越好 | $560.0M | — |
| 股东权益账面价值 | $1.2B | $370.1M |
| 总资产 | $3.7B | $1.1B |
| 负债/权益比越低杠杆越低 | 0.45× | — |
8季度趋势，按日历期对齐
现金及短期投资ANDEAPLS
| Q4 25 | $98.3M | $466.2M | ||
| Q3 25 | — | $479.2M | ||
| Q2 25 | — | $370.0M | ||
| Q1 25 | — | $358.4M | ||
| Q4 24 | $561.8M | $411.3M | ||
| Q3 24 | — | $396.9M | ||
| Q2 24 | — | $360.1M | ||
| Q1 24 | — | $325.9M |
总债务ANDEAPLS
| Q4 25 | $560.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $608.2M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $93.1M |
股东权益ANDEAPLS
| Q4 25 | $1.2B | $370.1M | ||
| Q3 25 | $1.2B | $401.2M | ||
| Q2 25 | $1.4B | $156.3M | ||
| Q1 25 | $1.4B | $164.2M | ||
| Q4 24 | $1.4B | $228.5M | ||
| Q3 24 | $1.3B | $237.1M | ||
| Q2 24 | $1.3B | $264.3M | ||
| Q1 24 | $1.3B | $266.7M |
总资产ANDEAPLS
| Q4 25 | $3.7B | $1.1B | ||
| Q3 25 | $3.3B | $1.1B | ||
| Q2 25 | $3.4B | $821.4M | ||
| Q1 25 | $3.8B | $807.3M | ||
| Q4 24 | $4.1B | $885.1M | ||
| Q3 24 | $3.4B | $901.9M | ||
| Q2 24 | $3.3B | $904.5M | ||
| Q1 24 | $3.3B | $831.9M |
负债/权益比ANDEAPLS
| Q4 25 | 0.45× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.45× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.35× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-6.2M | $-14.2M |
| 自由现金流经营现金流 - 资本支出 | $-77.1M | $-14.3M |
| 自由现金流率自由现金流/营收 | -23.4% | -7.1% |
| 资本支出强度资本支出/营收 | 21.5% | 0.1% |
| 现金转化率经营现金流/净利润 | -0.09× | — |
| 过去12个月自由现金流最近4个季度 | $-56.1M | $45.0M |
8季度趋势，按日历期对齐
经营现金流ANDEAPLS
| Q4 25 | $-6.2M | $-14.2M | ||
| Q3 25 | $233.9M | $108.5M | ||
| Q2 25 | $299.3M | $4.4M | ||
| Q1 25 | $-350.0M | $-53.4M | ||
| Q4 24 | $268.8M | $19.4M | ||
| Q3 24 | $-2.1M | $34.1M | ||
| Q2 24 | $304.4M | $-8.3M | ||
| Q1 24 | $-239.6M | $-133.0M |
自由现金流ANDEAPLS
| Q4 25 | $-77.1M | $-14.3M | ||
| Q3 25 | $167.0M | $108.3M | ||
| Q2 25 | $250.5M | $4.4M | ||
| Q1 25 | $-396.6M | $-53.4M | ||
| Q4 24 | $212.9M | $19.3M | ||
| Q3 24 | $-40.0M | — | ||
| Q2 24 | $275.8M | $-8.4M | ||
| Q1 24 | $-266.4M | $-133.3M |
自由现金流率ANDEAPLS
| Q4 25 | -23.4% | -7.1% | ||
| Q3 25 | 56.5% | 23.6% | ||
| Q2 25 | 46.8% | 2.5% | ||
| Q1 25 | -106.9% | -32.0% | ||
| Q4 24 | 63.1% | 9.1% | ||
| Q3 24 | -17.2% | — | ||
| Q2 24 | 56.0% | -4.2% | ||
| Q1 24 | -78.0% | -77.3% |
资本支出强度ANDEAPLS
| Q4 25 | 21.5% | 0.1% | ||
| Q3 25 | 22.6% | 0.0% | ||
| Q2 25 | 9.1% | 0.0% | ||
| Q1 25 | 12.6% | 0.0% | ||
| Q4 24 | 16.6% | 0.0% | ||
| Q3 24 | 16.3% | 0.0% | ||
| Q2 24 | 5.8% | 0.0% | ||
| Q1 24 | 7.8% | 0.2% |
现金转化率ANDEAPLS
| Q4 25 | -0.09× | — | ||
| Q3 25 | 11.61× | 0.50× | ||
| Q2 25 | 38.10× | — | ||
| Q1 25 | -1232.46× | — | ||
| Q4 24 | 5.96× | — | ||
| Q3 24 | -0.08× | — | ||
| Q2 24 | 8.46× | — | ||
| Q1 24 | -42.94× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ANDE
| Specialty And Primary Nutrients | $137.1M | 42% |
| Premium Ingredients | $66.1M | 20% |
| Segment Reporting Reconciling Item Other | $63.2M | 19% |
| Other | $63.1M | 19% |
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
